All Stories

  1. Convergent biology, divergent drivers: a cross-species comparison of human and canine invasive urothelial carcinoma
  2. Corrigendum to “Evidence-based medical therapy for mitral regurgitation in dogs” [J Vet Cardiol (2026) 10.1016/j.jvc.2026.04.006]
  3. Correction: Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses
  4. A One Health Approach to Parallel Drug Development
  5. New Frontiers of Drug Development Through the Use of New Approach Methodologies
  6. A Comprehensive Mathematical Model of Avidity in Cytokine Signaling
  7. Multi‐Institutional, Retrospective Evaluation of Risk Factors Predicting Complications Associated With Perineal Urethrostomy in Cats With Urethral Obstruction (2009–2019): 140 Cases
  8. Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs
  9. Are We Going to the Dogs? Human Disease Phenotypes in Canines
  10. Are We Going to the Dogs? Human Disease Phenotypes in Canines
  11. Gaps and paths forward in cancer pharmacology and translational research
  12. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  13. Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research
  14. Histologic and immunohistochemical characterization and frequency of rare subtypes of canine invasive urothelial carcinoma
  15. Innovative In Vitro-In Silico Platform for Dose–Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach
  16. Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease
  17. Prognostic value of plasma cortisol concentration in dogs with congestive heart failure
  18. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  19. Leveraging Canine Disease Models in Pharmaceutical Sciences: A One Health Path to Parallel Drug Development
  20. Multicenter Retrospective Evaluation of the Use of Lyophilized Platelets in Dogs
  21. Transmucosal detomidine gel induces emesis in approximately half of cats presenting for dietary indiscretion
  22. Development and characterization of chicken lung organoids for in vitro modeling of avian influenza virus-host cell interaction
  23. Urothelial genotoxicity of household chemicals in healthy canine urinary bladder organoids relative to observed urinary exposures in pet dogs
  24. Evidence-Based Medical Therapy for Mitral Regurgitation in Dogs
  25. Establishment and transcriptomic characterization of canine organoids from multiple tissues
  26. Retrospective Comparison of Outcomes From Septic Peritonitis of Gastrointestinal Versus Non‐Gastrointestinal Etiology in Dogs (2009–2022): 161 Cases
  27. A microfluidic platform for culturing and high-content imaging of adult stem cell-derived organoids
  28. Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease
  29. Development of a Time-based Drug Screening Platform for Improved Clinical Translation
  30. A Roadmap for the Future of Systems Biology in Cancer Research
  31. Retrospective Evaluation of Treatment and Survival of Blunt Trauma‐Associated Pneumothorax in Dogs: 89 Cases (2018–2022)
  32. Retrospective Evaluation of the Incidence and Risk Factors Associated With the Development of a Hepatopathy in Xylitol Ingestion: 95 Dogs (2018–2022)
  33. Interdisciplinary research seeks treatments and cures for diseases of animals and humans
  34. SUN-056 The National Biorepository and Resource for Pituitary Neuroendocrine Tumor Translational Research (BioPitNeT)
  35. Establishing a Canine Urothelial Organoid Repository: A Platform for Comparative and Translational Carcinoma Studies
  36. A comprehensive pharmacodynamic dataset reconciles 50 years of laboratory and clinical knowledge
  37. Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach
  38. Letter Regarding “Recommendations for a Complete Reporting of Statistical Methods in Veterinary Pharmacology”
  39. Optimizing First‐Line Therapeutics in Non‐Small Cell Lung Cancer: Insights From Joint Modeling and Large‐Scale Data Analysis
  40. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids
  41. Cancer Detection and Diagnosis
  42. Evolving value and validity of animal models in veterinary therapeutic research: Impact of scientific progress
  43. Restorative Effects of Synbiotics on Colonic Ultrastructure and Oxidative Stress in Dogs with Chronic Enteropathy
  44. OrganoidChip+: a Microfluidic Platform for Culturing, Staining, Immobilization, and High-Content Imaging of Adult Stem Cell-Derived Organoids
  45. Penicillin and Gentamicin Concentrations in the Uterine Fluid of Non‐Pregnant Mares Following a Single Intrauterine Infusion
  46. Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma
  47. Incidence of hypernatremia in dogs treated with multi-dose activated charcoal for acute toxicant ingestion: multi-center retrospective study (2018–2023)
  48. Pharmacokinetic evaluation and bioavailability of KPT-335 (Verdinexor) in cats
  49. Su1305: DUODENAL DNA METHYLATION PROFILES IN DOGS WITH CHRONIC INFLAMMATORY ENTEROPATHY TREATED WITH NOVEL SYNBIOTIC
  50. <span style="mso-bidi-font-weight: bold;">Spontaneous Canine Disease Models in Biomedical Science: A One Health Path to Predictive Drug Development
  51. Development and Characterization of Chicken Lung Organoids for Future In Vitro Modeling of Avian Influenza Virus-Host Cell Interaction
  52. A Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
  53. The association between non-depolarizing neuromuscular blockade agents and survival to discharge in dogs undergoing mechanical ventilation: a multi-center retrospective study of 227 dogs (2010–2020)
  54. Retrospective Evaluation of Complications Associated With Surgically Placed Gastrostomy Tubes in Dogs (2010–2020): 133 Cases
  55. Effects of a Western Diet on Colonic Dysbiosis, Bile Acid Dysmetabolism and Intestinal Inflammation in Clinically Healthy Dogs
  56. Incidence of hypernatremia in dogs treated with single dose activated charcoal for acute toxicant ingestion: multi-center retrospective study (2018–2023)
  57. A Novel Preclinical Model to Assess Intestinal Barrier Integrity Using Canine Enteroids and Colonoids
  58. A preliminary investigation in dogs to evaluate for post-anesthetic lung ultrasound findings suggestive of atelectasis
  59. A multi-stage feature selection method to improve classification of potential super-agers and cognitive decliners using structural brain MRI data—a UK biobank study
  60. Utilization of peripheral glucose and lactate differences in the diagnosis of feline arterial thromboembolism: a multi-center study
  61. Dose‐exposure‐response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin‐angiotensin‐aldosterone system in healthy dogs
  62. Frequency and progression of azotemia during acute and chronic treatment of congestive heart failure in cats
  63. Treatment of Canine Myxomatous Mitral Valve Disease:Current and Future Approaches
  64. University of Georgia College of Veterinary Medicine’s Precision One Health Initiative improves animal and human health by developing alternative models of disease
  65. Cisplatin-Induced Metabolic Responses Measured with Raman Spectroscopy in Cancer Cells, Spheroids, and Canine-Derived Organoids
  66. Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity
  67. 166 Development of non-model organoids in animal research: A paradigm shift in in vitro models
  68. Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs
  69. Evaluating the Bias of Two Point-of-Care Glucometers for Calves and Ewes: Awareness for Ruminant Practitioners
  70. Systemic absorption and gastrointestinal adverse effects from topical ketorolac and diclofenac ophthalmic solutions in healthy dogs
  71. Renin-Angiotensin Aldosterone System Modulation and Cardiovascular-Kidney-Metabolic Health
  72. Population Pharmacokinetics and Absolute Oral Bioavailability of Lasalocid after Single Intravenous and Intracrop Administration in Laying Hens
  73. Abstract PR002: Sarcomatoid Histological Variants of Canine Muscle-Invasive Bladder Cancer: Transcription Factor Activation Highlights Pathways of Epithelial-Mesenchymal Transformation Similar to Humans
  74. Retrospective evaluation of the prevalence and risk factors associated with red blood cell transfusions in cats with urethral obstruction (2009–2019): 575 cases
  75. Tu1739 MICRORNAS AS POTENTIAL BIOMARKERS FOR DIAGNOSIS AND MONITORING CHRONIC INFLAMMATORY ENTEROPATHY IN DOGS
  76. Randomized comparison between a forced air system and warm water bath for resuscitation of neonatal hypothermic calves with or without oral administration of caffeine
  77. Preclinical Modeling of Metabolic Syndrome to Study the Pleiotropic Effects of Novel Antidiabetic Therapy Independent of Obesity
  78. Experimental Methods for Establishing and Maintaining Canine Bladder Cancer Organoids
  79. A machine learning approach for potential Super‐Agers identification using neuronal functional connectivity networks
  80. Evaluation of different media compositions promoting hepatocyte differentiation in the canine liver organoid model
  81. Letter regarding “Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis”
  82. Comparison of Traditional Didactic Versus Additional Hands-On Simulation Training in the Performance of Basic Life Support in Veterinary Students—A Prospective, Blinded, Randomized Study
  83. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs
  84. Establishment and characterization of turtle liver organoids provides a potential model to decode their unique adaptations
  85. Effect of amlodipine on the circulating renin‐angiotensin‐aldosterone system in healthy cats
  86. Genetic Factors of Alzheimer’s Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study
  87. Adult Animal Stem Cell-Derived Organoids in Biomedical Research and the One Health Paradigm
  88. Leveraging the predictive power of 3D organoids in dogs to develop new treatments for man and man’s best friend
  89. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
  90. Retrospective evaluation of admission total plasma protein as a predictor of red blood cell transfusion requirement in dogs diagnosed with traumatic and nontraumatic hemoabdomen: 90 dogs (2009–2019)
  91. Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
  92. A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
  93. Exploring the Potential Links Between Gut Bacteria-Related Metabolites and the Risk of Cardiovascular Diseases
  94. Role of the tumour microenvironment in bladder cancer pathogenesis and value of the reverse translational approach: a tale of two species
  95. Effect of the Probiotic Bacillus subtilis DE-CA9TM on Fecal Scores, Serum Oxidative Stress Markers and Fecal and Serum Metabolome in Healthy Dogs
  96. Retrospective comparison of outcomes in septic peritonitis with or without closed-suction abdominal drainage in 115 dogs (2009–2019)
  97. Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses
  98. Gene Editing and Gene Therapy in Oncology
  99. Echocardiographic caudal vena cava measurements in healthy cats and in cats with congestive heart failure and non-cardiac causes of cavitary effusions
  100. Blood product usage and factors associated with transfusions in cats with hemoperitoneum: 33 cases (2018–2022)
  101. OrganoidChip facilitates hydrogel-free immobilization for fast and blur-free imaging of organoids
  102. Changes of Enterocyte Morphology and Enterocyte: Goblet Cell Ratios in Dogs with Protein-Losing and Non-Protein-Losing Chronic Enteropathies
  103. Increased drug concentration and repeated eye drop administration as strategies to optimize topical drug delivery: A fluorophotometric study in healthy dogs
  104. O62 | Population pharmacokinetics of sodium salicylate in chickens and turkeys – New insights into the drug's non‐linear elimination
  105. O89 | A novel biologically relevant canine in vitro model for the study of intestinal inflammation
  106. O59 | Breakthrough: A first‐in‐class virtual simulator for dose optimization of ACE inhibitors in veterinary cardiology
  107. O60 | Comparison of intestinal barrier integrity in conventional 2D cell lines and canine duodenal enteroids
  108. P51 | Evaluation of potential anti‐inflammatory and barrier‐enhancing effects of indoles on the canine duodenum using intestinal organoids
  109. O90 | Lung organoids as a novel model to study the pathogenesis of swine respiratory diseases
  110. O88 | Prediction of treatment response using canine urine‐derived bladder cancer organoids
  111. O63 | Population pharmacokinetics and absolute oral bioavailability of lasalocid ionophore in laying hens
  112. Concentrations of penicillin and gentamicin following intrauterine administration of two compounded formulations
  113. Leveraging Data from Spontaneous Animal Disease Models to Streamline Pharmaceutical Research: A Tale of Two Species
  114. Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs.
  115. Sa1767 SYNBIOTIC-IGY THERAPY MODULATES THE MUCOSAL MICROBIOME AND INFLAMMATORY INDICES IN DOGS WITH CHRONIC INFLAMMATORY ENTEROPATHY: A RANDOMIZED, CONTROLLED PILOT TRIAL
  116. Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study
  117. Canine Intestinal Organoids as a Novel In Vitro Model of Intestinal Drug Permeability: A Proof-of-Concept Study
  118. Abstract 2509: Similar variant histology and immune cell infiltration in canine and human muscle-invasive bladder cancer
  119. Exploring the secrets of super-aging: a UK Biobank study on brain health and cognitive function
  120. Understanding the background and clinical significance of the WHO, WOAH, and EMA classifications of antimicrobials to mitigate antimicrobial resistance
  121. Pharmacokinetics of intramuscular maropitant in pigs (Sus scrofa domesticus)
  122. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine
  123. Characterization of the First Turtle Organoids: A Model for Investigating Unique Adaptations with Biomedical Potential
  124. Dose–response of benazepril on biomarkers of the classical and alternative pathways of the renin–angiotensin–aldosterone system in dogs
  125. Retrospective evaluation of the effect of inhalant anesthesia on complications and recurrence rates in feline urethral obstruction
  126. Pharmacokinetic and pharmacodynamic properties of pantoprazole in calves
  127. Ionophore coccidiostats – disposition kinetics in laying hens and residues transfer to eggs
  128. Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer Using Large Database Reveals Potential Benefits of Scheduling Optimization
  129. Retrospective Comparison of Outcomes in Septic Peritonitis With or Without Closed-Suction Abdominal Drainage in 115 Dogs (2009-2019)
  130. Synbiotic-IgY Therapy Modulates the Mucosal Microbiome and Inflammatory Indices in Dogs with Chronic Inflammatory Enteropathy: A Randomized, Double-Blind, Placebo-Controlled Study
  131. Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma
  132. Comparison of the pharmacokinetics of continuous and intermittent infusions of ampicillin-sulbactam in dogs with septic peritonitis
  133. Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Translational Cardiovascular Medicine
  134. Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Veterinary Cardiology
  135. Linear external skeletal fixation applied in minimally invasive fashion for stabilization of nonarticular tibial fractures in dogs and cats
  136. Culture and characterization of canine and feline corneal epithelial organoids: A new tool for the study and treatment of corneal diseases
  137. Retrospective evaluation of risk factors for development of kidney injury after parenteral furosemide treatment of left‐sided congestive heart failure in dogs
  138. Kinetics and minimal inhibitory concentrations of ceftiofur in tear film following extended-release parenteral administration (Excede®) in dogs
  139. Bioenergetic and vascular predictors of potential super-ager and cognitive decline trajectories—a UK Biobank Random Forest classification study
  140. Ketogenic diets in healthy dogs induce gut and serum metabolome changes suggestive of anti‐tumourigenic effects: A model for human ketotherapy trials
  141. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs
  142. Differential Transcriptomic Profiles Following Stimulation with Lipopolysaccharide in Intestinal Organoids from Dogs with Inflammatory Bowel Disease and Intestinal Mast Cell Tumor
  143. A Multi-Tissue Comparison and Molecular Characterization of Canine Organoids
  144. Letter regarding “Gastrointestinal foreign bodies in pet pigs: 17 cases”
  145. Evaluation of the Use of External Skeletal Fixation in Minimally Invasive Fashion for the Treatment of Non-articular Tibial Fractures
  146. Abstract 3092: Urine-derived urinary carcinoma organoids: A novel tool for providing new insights into human and canine bladder cancer treatment
  147. Retrospective Evaluation of Clinical Bleeding in Dogs With Anticoagulant Rodenticide Toxicity—A Multi-Center Evaluation of 62 Cases (2010–2020)
  148. Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
  149. Using machine learning to predict COVID-19 infection and severity risk among 4510 aged adults: a UK Biobank cohort study
  150. SGLT2 Inhibitors and Potential Applications in Treating Metabolic Syndrome
  151. Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves
  152. Circulating renin‐angiotensin‐aldosterone system activity in cats with systemic hypertension or cardiomyopathy
  153. Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
  154. Canine Intestinal Organoids in a Dual-Chamber Permeable Support System
  155. Computed Tomographic Evaluation of Mid-thoracic Vertebral Corridors in Normal French Bulldogs
  156. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research
  157. Standardization and Maintenance of 3D Canine Hepatic and Intestinal Organoid Cultures for Use in Biomedical Research
  158. Differential Transcriptomic Profiles in Canine Intestinal Organoids Following Lipopolysaccharide Stimulation
  159. Suspected primary hyperreninism in a cat with malignant renal sarcoma and global renin‐angiotensin‐aldosterone system upregulation
  160. Multiomic analysis defines the first microRNA atlas across all small intestinal epithelial lineages and reveals novel markers of almost all major cell types
  161. Albumin in Tears Modulates Bacterial Susceptibility to Topical Antibiotics in Ophthalmology
  162. Harnessing the Biology of Canine Intestinal Organoids to Heighten Understanding of Inflammatory Bowel Disease Pathogenesis and Accelerate Drug Discovery: A One Health Approach
  163. Current diagnostics for chronic enteropathies in dogs
  164. Clinical efficacy of prebiotics and glycosaminoglycans versus placebo In dogs with food responsive enteropathy receiving a hydrolyzed diet: A pilot study
  165. 109 Diet-induced Clinical Responsiveness of Translational Dog Model for Human Western Diet (WD)-related Disease Research
  166. Pharmacokinetics of Pantoprazole and Pantoprazole Sulfone in Goats After Intravenous Administration: A Preliminary Report
  167. Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni
  168. CULTURE AND MAINTENANCE OF URINE-DERIVED, 3-DIMENSIONAL CANINE TRANSITIONAL CELL CARCINOMA ORGANOIDS
  169. Retrospective evaluation of a dose‐dependent effect of angiotensin‐converting enzyme inhibitors on long‐term outcome in dogs with cardiac disease
  170. Computed tomography evaluation of proposed implant corridors in canine thoracic vertebrae
  171. Inflammation, negative affect, and amyloid burden in Alzheimer’s disease: Insights from the kynurenine pathway
  172. Focused ultrasound of the caudal vena cava in dogs with cavitary effusions or congestive heart failure: A prospective, observational study
  173. Corrigendum: Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
  174. Gene Editing and Gene Therapy: Entering Uncharted Territory in Veterinary Oncology
  175. Radiation exposure associated with percutaneous fluoroscopically guided lag screw fixation for sacroiliac luxation in dogs
  176. Short‐term outcomes of 59 dogs treated for ilial body fractures with locking or non‐locking plates
  177. Su124 HOMOLOGY DIRECTED REPAIR IN CANINE DUODENAL ENTEROIDS TO MIMIC THE WILD-TYPE P-GLYCOPROTEIN MUTATION
  178. Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics
  179. Clinical Efficacy of Prebiotics and Glycosaminoglycans versus Placebo In Dogs with Food Responsive Enteropathy Receiving a Hydrolyzed Diet: A Pilot Study
  180. Effect of prazosin on feline recurrent urethral obstruction
  181. Presentation, Clinical Pathology Abnormalities, and Identification of Gastrointestinal Parasites in Camels (Camelus bactrianus and Camelus dromedarius) Presenting to Two North American Veterinary Teaching Hospitals. A Retrospective Study: 1980–2020
  182. Influence of Schirmer strip wetness on volume absorbed, volume recovered, and total protein content in canine tears
  183. A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
  184. Letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
  185. Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash Is Another Man’s Treasure
  186. Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer
  187. Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration
  188. Genetic Factors of Alzheimer’s Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study
  189. Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash is Another Man’s Treasure
  190. Genetics and Immunopathogenesis of Chronic Inflammatory Enteropathies in Dogs
  191. Impact of diurnal variation, sex, tear collection method, and disease state on tear protein levels in dogs
  192. Tear Film Pharmacokinetics and Systemic Absorption Following Topical Administration of 1% Prednisolone Acetate Ophthalmic Suspension in Dogs
  193. Pharmacokinetics of Oral Prednisone at Various Doses in Dogs: Preliminary Findings Using a Naïve Pooled-Data Approach
  194. Considerations in the extrapolation of drug toxicity between humans and dogs
  195. Evaluation of a Pasteurella multocida Respiratory Disease Induction Model for Goats (Capra aegagrus hircus)
  196. Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
  197. Determination of the milk pharmacokinetics and depletion of milk residues following intramammary administration of cephapirin sodium in lactating dairy goats
  198. Serum albumin and total protein concentration in the tear film of horses with healthy or diseased eyes
  199. Comparative Pharmacokinetics of Meloxicam Between Healthy Post-partum vs. Mid-lactation Dairy Cattle
  200. Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets
  201. Neuroinflammation, Depressive Affect, and Amyloid Burden in Alzheimer’s Disease: Insights from the Kynurenine Pathway
  202. Effects of the estrous cycle and pregnancy status on cardiovascular variables in healthy bitches
  203. An eye on the dog as the scientist's best friend for translational research in ophthalmology: Focus on the ocular surface
  204. Treatment With Hydrolyzed Diet Supplemented With Prebiotics and Glycosaminoglycans Alters Lipid Metabolism in Canine Inflammatory Bowel Disease
  205. Impact of acute conjunctivitis on ocular surface homeostasis in dogs
  206. Walking in the Light: How History of Physical Activity, Sunlight, and Vitamin D Account for Body Fat—A UK Biobank Study
  207. An Eye on the Dog as the Scientist’s Best Friend for Translational Research in Ophthalmology: Focus on the Ocular Surface
  208. Sa1976 POLYPHENOLS REVERSE THE PATHOLOGIC EFFECTS OF PALMITIC ACID AND HIGH FAT DIET IN CANINE ENTEROIDS
  209. Recapitulation of the accessible interface of biopsy-derived canine intestinal organoids to study epithelial-luminal interactions
  210. Evaluation of dose-response effects of short-term oral prednisone administration on clinicopathologic and hemodynamic variables in healthy dogs
  211. Harnessing The Biology of Intestinal Organoids To Accelerate Drug Discovery in Inflammatory Bowel Disease: A One Health Approach
  212. Serum Vitamin B12, and Related MTRR and Cubilin Genotypes, Predict Neural Outcomes across the AD Spectrum
  213. A Retrospective Clinical Investigation of the Safety and Adverse Effects of Pantoprazole in Hospitalized Ruminants
  214. Investigation of Schirmer tear test-1 for measurement of tear production in cats in various environmental settings and with different test durations
  215. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
  216. Apparent total tract digestibility, fecal characteristics, and blood parameters of healthy adult dogs fed high-fat diets
  217. Albumin Levels in Tear Film Modulate the Bioavailability of Medically-Relevant Topical Drugs
  218. CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors
  219. Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease
  220. Kinetics of Fluorescein in Tear Film After Eye Drop Instillation in Beagle Dogs: Does Size Really Matter?
  221. Nerve growth factor in dogs: Assessment of two immunoassays and selected ocular parameters following a nicergoline challenge per os
  222. In vitro Cytotoxicity and Pharmacokinetic Evaluation of Pharmacological Ascorbate in Dogs
  223. Aging-related changes in fluid intelligence, muscle and adipose mass, and sex-specific immunologic mediation: A longitudinal UK Biobank study
  224. Re: “Evaluation of Enrofloxacin for Use in Cryopreservation of Zebu Bull (Bos indicus) Semen” by Ishaq et al. (Biopreserv Biobank 2019;[Epub ahead of print]; DOI: 10.1089/bio.2018.0133)
  225. Pharmacokinetic Modeling of Ceftiofur Sodium Using Non-linear Mixed-Effects in Healthy Beagle Dogs
  226. Comparative pharmacokinetics of meloxicam between healthy postpartum versus mid-lactation dairy cows
  227. Fluorophotometric Assessment of Tear Volume and Turnover Rate in Healthy Dogs and Cats
  228. Clinicopathologic, hemodynamic, and echocardiographic effects of short-term oral administration of anti-inflammatory doses of prednisolone to systemically normal cats
  229. Nonlinear mixed‐effects pharmacokinetic modeling of the novel COX‐2 selective inhibitor vitacoxib in dogs
  230. Pharmacokinetic Modeling of Ceftiofur Sodium Using Nonlinear Mixed-Effects in Healthy Beagle Dogs
  231. Histamine-Induced Conjunctivitis and Breakdown of Blood–Tear Barrier in Dogs: A Model for Ocular Pharmacology and Therapeutics
  232. Microbiota-Related Changes in Unconjugated Fecal Bile Acids Are Associated With Naturally Occurring, Insulin-Dependent Diabetes Mellitus in Dogs
  233. The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
  234. A reduced Gompertz model for predicting tumor age using a population approach
  235. Effects of experimentally induced respiratory disease on the pharmacokinetics and tissue residues of tulathromycin in meat goats
  236. Indoleamine-pyrrole 2,3-dioxygenase-1 (IDO-1) mRNA is over-expressed in the duodenal mucosa and is negatively correlated with serum tryptophan concentrations in dogs with protein-losing enteropathy
  237. Interleukin‐13 and interleukin‐33 mRNA are underexpressed in the duodenal mucosa of German Shepherd dogs with chronic enteropathy
  238. Paper spray high-resolution accurate mass spectrometry for quantitation of voriconazole in equine tears
  239. Tear Fluid Pharmacokinetics Following Oral Prednisone Administration in Dogs With and Without Conjunctivitis
  240. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
  241. 449 – High Fat Ketogenic Diet Decreases Serum Lipid Metabolites in Healthy Dogs
  242. Sa1098 – Molecular Response of Canine Intestinal Organoids to Gastrointestinal Nematode Extracellular Vesicles
  243. Su1812 – Treatment with Hydrolyzed Diet Supplemented with Prebiotics and Glycosaminoglycans Improves Abnormalities in Lipid Metabolism in a Canine Model of Inflammatory Bowel Disease
  244. Su2043 – A Novel Canine Intestinal Organoid Model to Characterize Dose-Exposure-Response of Chemotherapeutic Drugs
  245. Derivation of adult canine intestinal organoids for translational research in gastroenterology
  246. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
  247. A Review of Relevant Therapeutic Targets for the Management of Congestive Heart Failure in Dogs: Present and Future Directions
  248. Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
  249. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation
  250. The Role of the Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review
  251. Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection
  252. Workshop Report: USP Workshop on Exploring the Science of Drug Absorption
  253. Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor
  254. Correlating Gastrointestinal Histopathologic Changes to Clinical Disease Activity in Dogs With Idiopathic Inflammatory Bowel Disease
  255. CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds against Hematological Malignancies
  256. Relative Oral Bioavailability of Two Amoxicillin–Clavulanic Acid Formulations in Healthy Dogs: A Pilot Study
  257. Clinical features of cats with aqueous tear deficiency: a retrospective case series of 10 patients (17 eyes)
  258. Adult Canine Intestinal Derived Organoids: A Novel In Vitro System for Translational Research in Comparative Gastroenterology
  259. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs
  260. Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation
  261. Comparative plasma and interstitial fluid pharmacokinetics and tissue residues of ceftiofur crystalline-free acid in cattle with induced coliform mastitis
  262. Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study
  263. Impact of Flow Rate, Collection Devices, and Extraction Methods on Tear Concentrations Following Oral Administration of Doxycycline in Dogs and Cats
  264. Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation
  265. Mo1059 - Comparison of Endoscopically (Egd/Colo) Procured Enteroids and Colonoids from Normal Dogs and Dogs with Naturally Occurring Chronic Enteropathies (IBD)
  266. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs
  267. Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation
  268. Effect of tear collection on lacrimal total protein content in dogs and cats: a comparison between Schirmer strips and ophthalmic sponges
  269. Comparison of milk and plasma pharmacokinetics of meloxicam in postpartum versus mid-lactation Holstein cows
  270. Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences
  271. Intestinal Stem Cells to Advance Drug Development, Precision, and Regenerative Medicine: A Paradigm Shift in Translational Research
  272. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics
  273. Model-Based Reverse Translation Between Veterinary and Human Medicine: The One Health Initiative
  274. Pharmacokinetics and adverse reactions to fentanyl transdermal patches in healthy and hospitalized calves
  275. Tear fluid collection in dogs and cats using ophthalmic sponges
  276. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats
  277. Position Paper: EUFEPS Network on Veterinary Medicines Initiative
  278. Multiple comparison procedure and modeling: a versatile tool for evaluating dose-response relationships in veterinary pharmacology - a case study with furosemide
  279. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment
  280. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics
  281. Chronobiology and Pharmacologic Modulation of the Renin–Angiotensin–Aldosterone System in Dogs: What Have We Learned?
  282. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs
  283. FIRST-IN-CLASS ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696 MODULATES THE DYNAMICS OF THE RENIN CASCADE AND NATRIURETIC PEPTIDES SYSTEM WITH SIGNIFICANT REDUCTION OF ALDOSTERONE EXPOSURE
  284. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs
  285. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis
  286. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology
  287. Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology
  288. Response to letter from Atkinset al. Capturing the dynamics of systemic Renin‐Angiotensin‐Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
  289. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs
  290. Pharmacokinetics of extravascular maropitant citrate in swine